Clinical Trial Update: Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating isoniazid dose adjustment by NAT2 genotype in pulmonary tuberculosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• ISONIAZID (ISONIAZID)

Snippet

Sponsor: University of Cologne | Conditions: Pulmonary Tuberculosis | Phase 3 | Status: TERMINATED